Patricia L. Allen

Patricia L. Allen discloses dealings in 4 companies, chiefly Alnylam Pharmaceuticals, Inc., Deciphera Pharmaceuticals, Inc. and Zenas BioPharma, Inc. We count 68 filings; the first trade dates from 25 October 2007 and the latest from 13 February 2026.

Market trades split into 6 purchases (€466k) and 57 sales (€2.9M). Sales outweigh purchases by €2.4M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 4 option exercises. Since January 2026: 4 purchases and no sales on the market.

Half of the purchases are above €96k and half below. Clusters matter here: 6 out of 6 purchases overlapped with buying by a colleague within 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. After 6 purchases with a full 90-day history, the hit rate stands at 33% and the median 90-day move at -31.5%. Past outcomes like these are no guarantee of what comes next.

On 13 February 2026 came the latest disclosure, an open-market purchase for €112k in Zenas BioPharma, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.